Table 2. BMI, laboratory parameters and LOS in the no leakage group: NAFLD-absent and NAFLD-present groups.
| No leakage-NAFLD group (n = 53) | No leakage+NAFLD group (n = 62) | |
|---|---|---|
| BMI, kg/m2, median (IQR) | 23.30 (21.33–24.34) | 25.71 (23.81–28.46)* |
| AST level, febrile phase, U/L, median (IQR) | 40 (25–61.50) | 43.5 (28.75–68.5) |
| ALT level, febrile phase, U/L, median (IQR) | 49 (30–71.50) | 59 (43.50–86)* |
| AST level, critical phase, U/L, median (IQR) | 79 (41–125) | 82 (47.25–135) |
| ALT level, critical phase, U/L, median (IQR) | 81 (44.50–139) | 86.5 (57.25–125.5) |
| Hemoconcentration, %, median (IQR) | 10.32 (7.55–13.71) | 11.02 (8.21–13.92) |
| Lowest platelet count, × 1,000/μL, median (IQR) | 73 (37.5–100) | 66.5 (34–109.75) |
| Albumin level, g/dL, median (IQR) | 3.5 (3.3–3.65) | 3.4 (3.2–3.7) |
| LOS, days, median (IQR) | 5 (4–6) | 5 (4–6.25) |
Abbreviations: NAFLD, nonalcoholic fatty liver disease; BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; IQR, interquartile range; LOS, length of hospital stay
The Mann-Whitney test was performed to assess differences in BMI, laboratory parameters and LOS between groups with and without NAFLD.
* Significantly different from patients in the no leakage-NAFLD group (p<0.05).